← Back to Search

SMART Interventions for Opioid Use Disorder

N/A

Waitlist Available

Research Sponsored by Karen Derefinko, PhD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Eligible of receipt of buprenorphine-naloxone medication as determined by Study Doctor

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 8 months

Awards & highlights

Study Summary

This trial will compare the effectiveness of two different interventions for helping people stick to their medication-assisted treatment for substance abuse.

Who is the study for?

This trial is for adults with Opioid Use Disorder who are eligible to receive buprenorphine-naloxone medication, as determined by the study doctor. Participants must have access to a telephone and be able to understand spoken English.Check my eligibility

What is being tested?

The SMART Trial is testing two interventions aimed at improving adherence to medication-assisted treatment: Contingency Management (CM), which rewards patients for meeting certain goals, and a combination of Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM).See study design

What are the potential side effects?

While specific side effects are not listed for the interventions being tested in this trial, common side effects associated with buprenorphine-naloxone include nausea, headache, dizziness, drowsiness, constipation, and sweating.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

The study doctor has approved me for buprenorphine-naloxone treatment.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 8 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 8 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 8 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Medication-Assisted Treatment (MAT) Adherence

Trial Design

3Treatment groups

Active Control

Group I: Contingency Management (CM)Active Control1 Intervention

CM is a behavioral method that employs external rewards for target behavior. Participants will receive gift cards for adhering to treatment (attending physician visits and being adherent to buprenorphine-naloxone) for their first 4 clinic visits.

Group II: Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM)Active Control1 Intervention

Participants will receive the BSM intervention at 4 timepoints.

Group III: BSM+CMActive Control2 Interventions

BSM+CM is a combination of the two other arms. Participants may be randomized to this arm only in stage 2 of the SMART design.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Karen Derefinko, PhDLead Sponsor

3 Previous Clinical Trials

367 Total Patients Enrolled

University of MemphisOTHER

70 Previous Clinical Trials

11,609 Total Patients Enrolled

University of New MexicoOTHER

372 Previous Clinical Trials

3,528,565 Total Patients Enrolled

Media Library

Brief Motivational Intervention plus Substance Free Activities Session Clinical Trial Eligibility Overview. Trial Name: NCT04080180 — N/A

Opioid Use Disorder Research Study Groups: Contingency Management (CM), Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM), BSM+CM

Opioid Use Disorder Clinical Trial 2023: Brief Motivational Intervention plus Substance Free Activities Session Highlights & Side Effects. Trial Name: NCT04080180 — N/A

Brief Motivational Intervention plus Substance Free Activities Session 2023 Treatment Timeline for Medical Study. Trial Name: NCT04080180 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers still enrolling people in this clinical trial?

"According to the latest information on clinicaltrials.gov, this trial is not currently looking for participants. This page was created on February 1st, 2022 and was last updated on April 13th, 2022. There are 547 other trials that are actively looking for patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence

Karen Derefinko, PhD 2022. "SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04080180.

All > Opioid Dependence > Probuphine